Kala Bio Inc (NAS:KALA)
$ 6.825 -0.04 (-0.58%) Market Cap: 19.22 Mil Enterprise Value: 4.76 Mil PE Ratio: 0 PB Ratio: 2.51 GF Score: 49/100

Kala Pharmaceuticals, Inc. - Special Call Transcript

Oct 27, 2020 / 12:30PM GMT
Release Date Price: $313.75 (-18.72%)
Operator

Good morning, and welcome to Kala Pharmaceuticals' EYSUVIS FDA approved conference call. Please be advised that today's conference call is being recorded. (Operator Instructions)

I would now like to turn the call over to Niranjan Kameswaran, Senior Vice President of Strategy for Kala Pharmaceuticals. Please proceed.

Niranjan Kameswaran
Kala Pharmaceuticals, Inc. - SVP of Strategy

Thank you, operator. Good morning, everyone. Welcome to our conference call to discuss the FDA approval of EYSUVIS. You can access our press release announcing the approval by going to the Investors section of our website at Kalarx.com. With me on today's call are: Mark Iwicki, Chairman, President and Chief Executive Officer; Todd Bazemore, Chief Operating Officer; Mary Reumuth, Chief Financial Officer; Kim Brazzell, Chief Medical Officer; and Hongming Chen, Chief Scientific Officer.

Before we begin, I would like to caution that comments made by management during this conference call about Kala's future expectations, plans and prospects are forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot